Drug Testing Procurement RFP Template: Sample Specifications for Federal Buyers
Quick answer: A federal drug testing RFP must specify the acquisition authority (FAR Part 12 commercial item, Part 13 simplified acquisition, or Part 15 negotiated procurement), the regulatory testing standard (49 CFR Part 40, HHS Mandatory Guidelines, or agency-specific authority), the technical specifications for collection devices and laboratory analysis (FDA 510(k) clearance, CLIA classification, SAMHSA certification), the Medical Review Officer process, chain-of-custody requirements, delivery and dispatch terms, and a clear evaluation rubric weighted between technical capability and price.
>
Key data points:
- Federal procurement spent more than $700 billion in fiscal year 2024 across all categories, with GSA Multiple Award Schedules accounting for roughly $45 billion in sales (GSA annual report data).
- Approximately 80% of federal civilian drug testing procurement flows through GSA Schedules, agency BPAs, or other established contract vehicles rather than open-market solicitation (industry estimate based on USAspending.gov category data).
- The Department of Transportation alone oversees regulated testing for an estimated 7 to 10 million federally regulated employees across aviation, rail, motor carrier, pipeline, and maritime sectors (DOT industry data).
- GAO audits of federal procurement frequently cite "inadequate specifications" and "evaluation criteria not aligned with statement of work" as leading causes of bid protest sustainment (GAO bid protest annual reports).
Last updated: 2026-06-02 · ~15 min read · Sources: FAR Parts 12, 13, 15; 49 CFR Part 40; HHS Mandatory Guidelines; GSA Schedules program data; GAO bid protest reports; USAspending.gov
A federal drug testing RFP is a regulatory document before it is a commercial document. The contracting officer, contracting officer's representative, and program manager who draft it operate within Federal Acquisition Regulation Part 12 if the requirement is a commercial item, Part 13 if simplified acquisition thresholds apply, or Part 15 if negotiated procurement is the chosen path. The technical specifications must align with the testing authority that governs the agency's workforce — 49 CFR Part 40 for transportation-regulated personnel, the HHS Mandatory Guidelines for non-DOT federal employees, or agency-specific statutory authority for law enforcement and intelligence components. A solicitation that confuses these frameworks is a solicitation that produces non-compliant bids, sustained protests, and rework.
This article presents a federal RFP template structure for drug testing procurement, with sample specifications that align with FAR-compliant practice, current regulatory standards, and the procurement realities federal buyers face. American Screening Corp. (ASC) is positioned in this market as an FDA 510(k) Cleared, CLIA-Waived, ISO 13485 supplier with a Shreveport, Louisiana headquarters, same-day dispatch before 2 p.m. Central, and NET-30 terms available to qualified federal purchasers.
The acquisition decision: which FAR pathway applies
The first decision in any federal drug testing procurement is the acquisition pathway. The pathway determines which evaluation procedures apply, which solicitation format is appropriate, what competition is required, and how the award decision must be documented. Procurement officers who skip this analysis and reach immediately for a familiar RFP format frequently produce procurements that are technically out of compliance with FAR Part 6 (full and open competition) or FAR Part 8 (required sources).
Drug testing supplies — collection cups, custody and control forms, oral fluid devices, alcohol screening devices — are commercial items as defined at FAR 2.101. They are sold to the general public, they are sold to commercial buyers in substantial quantities, and they are sold to federal buyers without modification. That classification matters because FAR Part 12 establishes streamlined procedures for commercial item acquisition that simplify solicitation, evaluation, and contract terms relative to non-commercial procurement. Federal buyers should default to Part 12 procedures for drug testing supply procurement and reach for non-commercial procedures only when the requirement is genuinely non-commercial (a custom laboratory information system integration, for example, would not be a commercial item).
The dollar threshold then determines whether simplified acquisition under FAR Part 13 is available. As of recent threshold adjustments, the Simplified Acquisition Threshold is $250,000 and the micro-purchase threshold is $10,000 for most procurements. Drug testing supply requirements below the SAT can be acquired through simplified procedures, which compress the timeline and reduce documentation burden. Above the SAT, the procurement typically proceeds under FAR Part 15 negotiated procurement or through an existing GSA Schedule order.
The required-sources analysis under FAR Part 8 is the next checkpoint. AbilityOne and Federal Prison Industries have priority status for specific product categories. GSA Multiple Award Schedules are a required consideration under FAR 8.4. Agency-specific contract vehicles such as Department of Veterans Affairs Federal Supply Schedules and Department of Defense indefinite-delivery contracts may apply. The contracting officer must document the required-sources analysis before proceeding to open-market solicitation.
Comparison: four federal procurement pathways for drug testing
The four primary pathways have meaningfully different documentation burdens, competition requirements, and award timelines. Procurement officers should select the pathway that matches the requirement's dollar value, urgency, and complexity rather than defaulting to the pathway most familiar to the office.
| Pathway | Governing authority | Threshold / scope | Competition required | Typical award timeline | When appropriate |
|---|---|---|---|---|---|
| GSA Multiple Award Schedule order | FAR Subpart 8.4 | No upper limit; subject to MAS pricing | Minimum of three quotes for orders over Micro-Purchase Threshold | 30–60 days | Established Schedule pricing exists; agency has Schedule access |
| Simplified acquisition | FAR Part 13 | Up to $250,000 (SAT) | Maximum practicable competition; streamlined | 30–45 days | Routine supply, established commercial market |
| Open-market commercial item | FAR Part 12 with Part 13 or 15 | No upper limit | Full and open competition under FAR Part 6 unless exception applies | 90–180 days | No Schedule pricing available; complex specifications |
| Sole-source / limited competition | FAR 6.302 exceptions | Justified by statute | Justification and Approval (J&A) required | Variable; J&A adds 30–60 days | Only one responsible source; urgent and compelling need |
For drug testing supplies, GSA Schedule ordering is the most efficient pathway when the agency has Schedule access and the required products are listed. Simplified acquisition is appropriate for non-Schedule small-dollar requirements. Open-market procurement under FAR Part 12 with full and open competition is the default for large, complex, or multi-year requirements where Schedule pricing does not cover the scope. Sole-source justification requires extraordinary documentation and is rarely defensible for commodity supplies; contracting officers should not pursue sole source for drug testing procurement except in genuine urgent and compelling circumstances.
The technical specifications section: what to require
Federal drug testing RFPs frequently fail because the technical specifications section either repeats marketing language from a preferred vendor or omits the regulatory anchors that determine compliance. A defensible specification section addresses six categories: regulatory clearance, intended use and CLIA classification, panel specifications, chain of custody, laboratory analysis, and quality system.
Regulatory clearance. Specifications must require FDA 510(k) clearance for in vitro diagnostic drug screening devices used in workplace and clinical testing under 21 CFR Part 866 Subpart E. The 510(k) number should be provided in the bidder's response. Devices marketed as Research Use Only or Investigational Use Only are not acceptable for workplace screening and should be expressly excluded.
Intended use and CLIA classification. Specifications must address the testing environment. Point-of-collection testing at a non-laboratory site requires CLIA-Waived classification. Laboratory-based testing requires the laboratory to hold a CLIA certificate of compliance or accreditation. Specifications should require the bidder to identify the CLIA classification of each proposed device.
Panel specifications. The drug panel must be specified by analyte and by cutoff concentration. Federal workplace testing under HHS Mandatory Guidelines uses the five-drug panel (marijuana metabolite, cocaine metabolite, opiates, phencyclidine, amphetamines) with specific cutoff concentrations defined in the guidelines. DOT regulated testing under 49 CFR Part 40 follows the HHS panel with expanded opiate testing. Agency-specific panels may be authorized — federal law enforcement components frequently add benzodiazepines, methamphetamine isomers, and synthetic opioids. Specifications must state the panel by analyte and cutoff, not by trade name.
Chain of custody. Specifications must require Federal Drug Testing Custody and Control Forms (OMB Control Number 0930-0158) for DOT and HHS-regulated testing. Non-regulated federal testing may use a non-federal CCF with matching field inventory. Lot-coded collection devices with traceable certificates of analysis should be required as a baseline. ASC's collection devices ship with lot codes and QR-linked certificates of analysis specifically to support federal procurement traceability requirements.
Laboratory analysis. For HHS-regulated and DOT-regulated specimens, the laboratory must hold SAMHSA NLCP certification. For non-regulated federal testing, CAP or CLIA accreditation is the minimum. Confirmatory testing by GC-MS or LC-MS/MS is required for any non-negative initial screening result. Specifications should state the required confirmatory methodology and the required reporting timeline.
Quality system. Specifications should require the bidder to identify its quality management system. ISO 13485 certification is the established standard for medical device manufacturers and represents the highest quality-system tier in this category. ASC operates under ISO 13485 quality systems.
The Medical Review Officer specification
Federal drug testing programs require Medical Review Officer review of non-negative results under DOT 49 CFR Part 40 and HHS Mandatory Guidelines. The RFP must specify whether MRO services are within scope, who provides them, and how they are priced.
MRO services in volume contracts are typically priced at $10–$25 per file review, with the variance driven by panel complexity, additional analyte review, and physician-to-donor contact requirements. Procurement files should document the price benchmark to defend the award against subsequent audit. The RFP should require bidders to identify the MRO physician's credentials (board certification in occupational medicine, addiction medicine, or related field; MROCC or AAMRO certification), describe the donor contact process, and specify the turnaround time from laboratory result to MRO-reported result.
For federal agencies that retain MRO services internally, the RFP should specify the laboratory's process for releasing non-negative results to the agency MRO and for documenting that release on the CCF. For federal agencies that contract MRO services through the supply vendor, the RFP should include MRO services in the technical evaluation criteria and in the price evaluation as a separate line item.
Chain of custody, retention, and litigation support
Federal drug testing programs frequently produce results that are litigated — in arbitration under collective bargaining agreements, in Merit Systems Protection Board appeals, in administrative removal actions, and in occasional criminal proceedings. The RFP must address custody documentation, specimen retention, and litigation support so that the resulting contract supports the agency's defense if a result is challenged.
Chain-of-custody specifications should require continuous documented custody from donor through collector, courier, laboratory, and storage. The bidder should describe its custody process at each transfer node. Lot-coded collection devices with QR-linked certificates of analysis should be required for traceability.
Specimen retention specifications should require minimum one-year retention for positive results under SAMHSA guidelines, with extended retention through litigation exhaustion for any specimen subject to administrative or judicial proceedings. The RFP should specify which party bears retention costs for extended litigation holds and how retention is documented.
Litigation support specifications should require the laboratory to make analysts available for testimony, to provide certified business records under FRE 902(11), and to support the MRO with documentation as needed. The RFP should specify the rate at which testimony will be billed (typically expert hourly rates with travel and per diem) and the protocol for subpoena response.
Past performance and small business considerations
Federal procurement evaluation under FAR Part 15 typically includes past performance as a non-price factor. The RFP must specify the relevant period (commonly three years), the relevance criteria (similar dollar value, similar scope, similar federal customer base), and the data sources (CPARS, PPIRS, references). For drug testing procurement, relevant past performance includes federal agency contracts, DOT-regulated contractor programs, large-employer programs of similar scale, and judicial or correctional programs.
Small business considerations require analysis under FAR Part 19. The RFP must address whether the requirement will be set aside for small business, small disadvantaged business, 8(a), HUBZone, service-disabled veteran-owned, or women-owned small business. The market research underlying the set-aside decision should be documented in the procurement file. For drug testing supply procurement, the market is sufficiently competitive that small business set-aside is frequently appropriate and the contracting officer should evaluate the small business pool before proceeding to full and open competition.
Evaluation criteria and award decision
The evaluation criteria section is where most federal drug testing RFPs go wrong. Generic criteria such as "technical capability" and "price" without weighting, sub-factors, or evaluation methodology produce evaluations that cannot survive bid protest. The evaluation section should specify the factors, the relative weight of each factor, the sub-factors within each factor, and the methodology for assigning ratings.
A defensible structure for a drug testing RFP evaluation might allocate 40 percent to technical capability (with sub-factors for regulatory clearance, panel specification compliance, chain-of-custody documentation, and quality system), 25 percent to past performance, 25 percent to price, and 10 percent to delivery and logistics (including same-day dispatch capability, geographic coverage, and NET-30 terms). The specific weights should align with agency priorities; the principle is that the weights are documented before proposals are received and the rating methodology is consistent across offerors.
The award decision should be documented in a source selection decision memorandum that addresses each evaluation factor, explains the trade-off if any was made between technical capability and price, and references the underlying evaluation reports. For best-value trade-offs under FAR 15.101-1, the contracting officer must explicitly justify paying a price premium for higher technical or past-performance ratings. For lowest-price technically-acceptable awards under FAR 15.101-2, the decision is more straightforward but the technical acceptability finding must still be documented.
Statistics and procurement context
Federal procurement is a large market with predictable failure patterns. "Approximately 80% of federal civilian drug testing procurement flows through GSA Schedules, agency BPAs, or other established contract vehicles rather than open-market solicitation" (industry composite based on USAspending.gov data). Procurement officers benefit from understanding that the market expects Schedule-based ordering and that open-market solicitations frequently produce non-responsive bids from vendors who are not staffed to support full FAR Part 15 procurement.
"GAO bid protest reports consistently identify inadequate technical specifications, evaluation criteria misalignment, and undocumented past performance evaluations as leading causes of protest sustainment" (GAO annual bid protest reports). Procurement officers can substantially reduce protest risk by drafting specifications that anchor to regulatory citations (FDA 510(k), CLIA classification, SAMHSA certification, ISO 13485) rather than to vendor-specific feature lists.
"The Department of Transportation alone oversees regulated testing for an estimated 7 to 10 million federally regulated employees across aviation, rail, motor carrier, pipeline, and maritime sectors" (DOT and industry trade association data). The scale of DOT-regulated procurement means that even small per-test pricing differences translate into seven-figure annual budget implications, and procurement files benefit from documenting the price benchmark per test, per panel, and per MRO review against published market data.
ASC's federal market positioning includes FDA 510(k) Cleared collection devices, CLIA-Waived classification for point-of-collection products, SAMHSA-aligned chain-of-custody documentation, ISO 13485 quality systems, same-day dispatch from Shreveport, Louisiana before 2 p.m. Central, NET-30 terms for qualified federal purchasers, and volume pricing structured at 10, 50, 100, 500, and 1,000-plus tiers that aligns with federal task-order quantities.
Practical procurement checklist
The following items should appear in every federal drug testing RFP. Contracting officers can lift this list verbatim into a solicitation development worksheet.
- Document the acquisition pathway analysis (FAR Part 12, Part 13, Part 15, or Schedule order).
- Document the required-sources analysis under FAR Part 8 (AbilityOne, FPI, GSA Schedule).
- Document the small business set-aside analysis under FAR Part 19.
- Specify the testing authority (49 CFR Part 40, HHS Mandatory Guidelines, agency-specific).
- Specify FDA 510(k) clearance requirement with 510(k) number identification in bid response.
- Specify CLIA classification requirement aligned with testing environment.
- Specify the drug panel by analyte and cutoff concentration.
- Specify chain-of-custody documentation requirements including OMB-approved CCF.
- Specify SAMHSA NLCP laboratory certification for regulated specimens.
- Specify ISO 13485 quality system as a baseline requirement.
- Specify MRO services and pricing at $10–$25 per file review benchmark.
- Specify specimen retention through litigation exhaustion.
- Specify delivery and dispatch terms including same-day capability.
- Specify evaluation factors, sub-factors, and weighting before release.
- Specify NET-30 or other payment terms aligned with Prompt Payment Act.
Frequently asked questions
What is the difference between a GSA Schedule order and an open-market drug testing procurement?
A GSA Schedule order is placed under an existing Multiple Award Schedule contract negotiated by GSA, with pricing, terms, and conditions already established. The ordering agency runs a Schedule competition under FAR Subpart 8.4 with minimum quote requirements but compressed timelines. An open-market procurement is a fresh solicitation under FAR Part 13 or Part 15 with full FAR Part 6 competition. Schedule orders are typically faster, less labor-intensive, and lower-risk for the contracting officer.
Can a federal agency sole-source drug testing supplies?
Sole-source procurement under FAR 6.302 requires a Justification and Approval that documents one of the statutory exceptions, most commonly that only one responsible source can satisfy the requirement or that an urgent and compelling need precludes competition. For commodity supplies like drug testing devices, sole-source justification is rarely defensible because the market is competitive. Contracting officers should pursue Schedule orders or competed open-market procurement rather than sole source.
What is FAR Part 12 and why does it matter for drug testing procurement?
FAR Part 12 establishes streamlined procedures for the acquisition of commercial items, which are defined at FAR 2.101 to include items sold in substantial quantities to the general public. Drug testing supplies meet the commercial item definition. Part 12 procedures simplify solicitation format, restrict the contracting officer's ability to require non-commercial terms, and align federal procurement with commercial practice. Procurement officers should default to Part 12 for drug testing supply procurement.
Are drug testing supplies subject to the Trade Agreements Act?
The Trade Agreements Act applies to acquisitions above specified dollar thresholds and requires that end products be substantially transformed in the United States or in a designated country. For drug testing supplies above the TAA threshold, contracting officers should require certification of country of origin and verify that designated country status applies. ASC's Shreveport, Louisiana manufacturing and assembly operations support TAA compliance documentation for federal procurement.
What is the difference between HHS Mandatory Guidelines and DOT 49 CFR Part 40?
The HHS Mandatory Guidelines govern federal workplace drug testing for executive branch civilian employees under Executive Order 12564. The DOT 49 CFR Part 40 governs transportation-regulated testing across aviation, rail, motor carrier, pipeline, and maritime sectors. The two frameworks share the foundational five-drug panel and SAMHSA laboratory certification requirement but differ in collector qualification, observed-collection triggers, and reporting structure. Procurement officers must identify which framework governs the requirement before specifying.
How do federal agencies handle Medical Review Officer services in procurement?
Federal agencies handle MRO services in one of three configurations. Some agencies retain MRO services internally through agency physicians and require laboratory vendors to release results directly to the agency MRO. Other agencies contract MRO services through the supply vendor and treat MRO as a contracted service line. A third configuration is a separate MRO contract awarded independently of the supply contract. The RFP must specify which configuration applies; MRO file review pricing typically benchmarks at $10–$25 per file in volume.
What is past performance evaluation and how is it documented for federal RFPs?
Past performance evaluation under FAR Part 15 assesses the bidder's track record on relevant prior contracts. Data sources include the Contractor Performance Assessment Reporting System (CPARS), the Past Performance Information Retrieval System (PPIRS), customer references, and information from other federal agencies. The RFP must specify the period of relevance, the relevance criteria, and the rating methodology. Bidders typically submit a past performance volume with relevant prior contracts identified.
What evaluation methodology is appropriate for drug testing supply procurement?
Best-value trade-off under FAR 15.101-1 and lowest-price technically-acceptable under FAR 15.101-2 are the two principal methodologies. For commodity supplies with mature commercial markets, LPTA is often appropriate provided the technical acceptability criteria are robust (regulatory clearance, CLIA classification, SAMHSA certification, panel compliance). For procurement requiring complex logistics, MRO services integration, or specialty panels, best-value trade-off may be appropriate to allow the contracting officer to pay a premium for superior technical capability.
How long does a typical federal drug testing RFP take from release to award?
Schedule orders close in 30 to 60 days from release to award. Simplified acquisitions typically close in 30 to 45 days. Open-market commercial item procurements under FAR Part 15 typically run 90 to 180 days. Sole-source procurements add 30 to 60 days for J&A development and approval. Federal buyers under time pressure should default to Schedule orders or simplified acquisition when the requirement permits.
How does ASC support federal procurement specifically?
American Screening Corp. supports federal procurement through FDA 510(k) Cleared products, CLIA-Waived classification, SAMHSA-aligned chain-of-custody documentation, ISO 13485 quality systems, same-day dispatch from Shreveport, Louisiana before 2 p.m. Central, NET-30 terms for qualified federal purchasers, TAA-compliant manufacturing documentation, and a federal dealer registration program that streamlines onboarding for federal procurement officers. Volume pricing is structured at 10, 50, 100, 500, and 1,000-plus tiers to align with federal task-order quantities, and our Federal Agencies industry program consolidates the federal offering into a single procurement package.
Key takeaways
- Federal drug testing RFPs are regulatory documents first; FAR pathway selection and required-sources analysis must precede specification drafting.
- GSA Schedule orders, simplified acquisition, open-market commercial item procurement, and sole-source pathways have distinct documentation and competition requirements.
- Technical specifications must anchor to regulatory citations (FDA 510(k), CLIA, SAMHSA, ISO 13485) rather than vendor-specific feature lists.
- Medical Review Officer services benchmark at $10–$25 per file review in volume; the RFP must specify the MRO configuration.
- Evaluation criteria, sub-factors, and weighting must be documented before solicitation release to support source selection defensibility.
- ASC's FDA 510(k), CLIA-Waived, ISO 13485 product line with Shreveport same-day dispatch and NET-30 terms supports federal procurement at scale.
Related reading
- Chain of Custody for Court-Defensible Drug Testing: A Step-by-Step Procurement Checklist
- Treatment Center Drug Screening Programs: Volume Pricing and Subscribe-and-Save Math
- FDA 510(k) Cleared vs Investigational Drug Tests: Procurement Risk Guide
Bottom CTA
Federal contracting officers, program managers, and contracting officer's representatives drafting drug testing solicitations can shorten the development cycle and reduce protest risk by anchoring technical specifications to ASC's published regulatory documentation. To receive specification language, 510(k) clearance documentation, CLIA classification statements, SAMHSA-aligned custody templates, and ISO 13485 quality system certifications for use in federal RFP development, request a federal procurement quote. NET-30 terms are available for qualified federal purchasers, same-day dispatch from Shreveport, Louisiana applies to orders placed before 2 p.m. Central, and the federal dealer registration program consolidates onboarding documentation for federal procurement officers.
Author note: Brigadier General (Retired) Marcus Pritchett is a Federal Procurement Advisor at American Screening Corp. He served as a contracting officer and program manager across thirty years of federal acquisition practice, including direct responsibility for medical and life-sciences procurement portfolios exceeding $400 million in aggregate contract value. He holds DAWIA Level III certification in Contracting and advises federal procurement teams on commercial item acquisition, simplified acquisition, and negotiated procurement under FAR Parts 12, 13, and 15. ASC is an FDA 510(k) Cleared, CLIA-Waived, ISO 13485 supplier headquartered in Shreveport, Louisiana, with same-day dispatch before 2 p.m. Central and NET-30 terms available for qualified federal purchasers.
